# Johnson & Johnson oncology clinical developments

> Developing situation record from CLSTR: https://clstr.news/situations/johnson-johnson-oncology-clinical-developments
> Updated: 2026-11-06T08:08:00.000Z. Sources: 3. Developments: 2.

Johnson & Johnson reported positive results from several oncology clinical trials. Data presented at the European Society for Medical Oncology Congress indicated that the drug Erleada, when used in combination with androgen deprivation therapy, showed a 62% reduction in the risk of recurrence or death for high-risk prostate cancer patients. Additionally, early-stage trials for the investigational drug JNJ-6143 demonstrated anti-tumor activity in patients with advanced prostate cancer, while the RYBREVANT FASPRO regimen achieved a 77% overall response rate in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Following these developments, the US Food and Drug Administration granted accelerated approval to Rybrevant Faspro for treating adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed after platinum-based chemotherapy and checkpoint inhibitor treatment. This marks the first indication for the EGFR-MET bispecific antibody beyond non-small cell lung cancer. Clinical data from the Phase Ib/II OrigAMI-4 trial showed a 42% confirmed overall response rate in the approved patient group.

## Claims

- The FDA granted accelerated approval to Johnson & Johnson’s Rybrevant Faspro for recurrent or metastatic head and neck squamous cell carcinoma. (reported by 3 sources)
- Rybrevant Faspro is an EGFR-MET bispecific antibody. (reported by 3 sources)
- The Phase Ib/II OrigAMI-4 trial showed a 42% response rate among 102 patients. (reported by 3 sources)
- The approval excludes patients with HPV-associated oropharyngeal squamous cell carcinoma. (reported by 2 sources)
- Rybrevant Faspro is administered via subcutaneous injection. (reported by 2 sources)
- Serious adverse reactions occurred in 39% of patients in the OrigAMI-4 trial. (reported by 1 source)
- Fatal adverse reactions occurred in 6% of patients in the OrigAMI-4 trial. (reported by 1 source)
- Johnson & Johnson stock rose 0.35% to $273.27 following the announcement. (reported by 1 source)

## Timeline

### 2026-11-06: Johnson & Johnson receives FDA accelerated approval for Rybrevant Faspro

The FDA granted accelerated approval to Johnson & Johnson’s Rybrevant Faspro for treating certain recurrent or metastatic head and neck squamous cell carcinomas.

3 sources. https://clstr.news/cluster/johnson-johnson-receives-fda-accelerated-approval-for-rybrevant-faspro

### 2026-10-24: Johnson & Johnson reports positive clinical trial results for cancer treatments

Johnson & Johnson announced positive clinical data for several cancer therapies, including Erleada for prostate cancer and the RYBREVANT FASPRO regimen for head and neck squamous cell carcinoma.

7 sources. https://clstr.news/cluster/fda-approves-once-weekly-insulin-awiqli-for-children-with-type-2-diabetes

---
Cite as: Johnson & Johnson oncology clinical developments. CLSTR, https://clstr.news/situations/johnson-johnson-oncology-clinical-developments